Amgen Inc and Merck & Co Inc have announced plans to collaborate on the development of a new combination therapy for advanced melanoma. This will combine Amgen’s oncolytic virus product with Merck’s PD-1 inhibitor. ---Subscribe to MedNous to access this article--- Clinical Research Company News
